SHENZHEN, CHINA, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008"), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world's largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.About CMS-D008CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the Phas...

香港, 2026年6月8日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）宣布与箕星药业（以下简称"箕星"）达成资产收购协议 (The Asset Purchase Agreement)，获得LNZ100（1.44% 醋克利定，美国商品名VIZZ）在大中华区（包含中国大陆，中国香港，中国澳门和中国台湾地区）的开发、生产与商业化权益。根据协议，云顶新耀将向箕星药业支付首付款以及开发里程碑付款。作为本协议的一部分，云顶&...

HONG KONG, Jun 8, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”). Under the agreement, Everest has acquired the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest will pay an upfront payment and potential development milestone payments. As part of this agreement, Everest will be assigned and transferred the rights and obligations under the LENZ License Agreement entered into by CORXEL in April 2022 and certain related ancillary agreements. This transaction is expected to further expand the Company’s innovative product portfolio, strengthen its presence in ophthalmology, and enhance overall strategic synergies across its business.LNZ100 is a once-daily prescription eye drop indicated for the treatment of presbyopia. Its active ingredient, aceclidine, is a small molecule acetylcholine receptor agonist that causes pupil contraction, or miosis, creating a pinhole effect that improves near vision. ...

OTTAWA, ON, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the. Air Quality Assessment ("AQA" or the "Study") for its 100%-owned Lac Knife Graphite Project (the "Project") located in northeastern Quebec.The Study was completed by WSP Canada Inc. ("WSP"), one of the world's leading engineering and environmental consulting firms, under the supervision and management of IOS Geosciences Inc. ("IOS"), as part of the environmental studies supporting the advancement of Lac Knife toward future permitting and development.The AQA evaluated emissions associated with the proposed open pit mine, processing facility, tailings storage facility, stockpiles, haul roads, crushing operations, and supporting infrastructure under conservative maximum operating scenarios. Atmospheric dispersion modelling using Aeromod software, was completed in accordance with the requirements of Quebec's Reglement sur l'assainissement de l'atmosph...

深圳, 2026年6月8日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司（867.HK/8A8.SG）（“康哲药业”）欣然宣布，其自主研发的创新药INHBE小核酸药物CMS-D008注射液（“CMS-D008”）的临床前结果在第86届美国糖尿病协会（ADA）大会（2026年6月5-8日，美国新奥尔良）以壁报形式发布。ADA大会作为全球糖尿病及代谢疾病领域规模最大、最具权威影响力的年度学术风向标，此次汇聚了来自世...

HONG KONG, Jun 7, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) will host a "Hong Kong Tech Pavilion" at Viva Technology (VivaTech) 2026, Europe’s premier annual startup and technology summit in Paris, from next Wednesday, 17 to Saturday, 20 June. In collaboration with our strategic partner, the Hong Kong Economic and Trade Office in Brussels, the Pavilion will bring together 24 Hong Kong startups to showcase innovations in artificial intelligence and robotics, health technology, and sustainability and climate technology. A series of thematic seminars, startup pitching sessions, and networking receptions will also be held to facilitate exchanges between global investors, buyers, and Hong Kong startups, fostering international collaboration. Several key partners, including Hong Kong Science and Technology Parks Corporation, Hong Kong Polytechnic University, Hong Kong Productivity Council, Hong Kong University of Science and Technology, and Cyberport, support the initiative.HKTDC’s Chris Lo, Regional Director, Europe, Central Asia & Israel, stated: "Hong Kong is actively developing into an international i...